Search results for Bamlanivimab
Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade, ProteoGenix, PX-TA1031
Description of Bamlanivimab Biosimilar - Anti-Covid Spike RBD mAb - Research Grade General information on Anti-SARS-CoV2 Spike RBD (Bamlanivimab) Monoclonal Antibody Bamlanivimab is a synthetic monoclonal antibody (mAb) that was developped from the first blood samples from COVID-19 recovered patients in the United States. Bamlanivimab is a neutralizing IgG1 mAb targetting the SARS-CoV-2 spike, which prevents the virus from entering human cells. It has been found to recognize first type and variants referenced as PX-COV-P046 and PX-COV-P052.
Host
Reactivity
Applications
Conjugation
Bamlanivimab, Abbexa, abx831593
Bamlanivimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting SARS-CoV-2 RBD, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Bamlanivimab Biosimilar - Research Grade, ichor.bio, ICH5180
Detects SARS-CoV-2
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Research Grade Bamlanivimab (VK565036), abinScience, VK565036
Host
Human
Reactivity
SARS-CoV-2 (2019-nCoV)
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Conjugation
Please provide the required information below so that we can quickly source your products.